CRBP Strangle Strategy
CRBP (Corbus Pharmaceuticals Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
CRBP (Corbus Pharmaceuticals Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $152.3M, a beta of 2.68 versus the broader market, a 52-week range of 6.72-20.56, average daily share volume of 250K, a public-listing history dating back to 2014, approximately 28 full-time employees. These structural characteristics shape how CRBP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.68 indicates CRBP has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on CRBP?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current CRBP snapshot
As of May 15, 2026, spot at $11.11, ATM IV 130.10%, IV rank 38.80%, expected move 37.30%. The strangle on CRBP below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on CRBP specifically: CRBP IV at 130.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 37.30% (roughly $4.14 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CRBP expiries trade a higher absolute premium for lower per-day decay. Position sizing on CRBP should anchor to the underlying notional of $11.11 per share and to the trader's directional view on CRBP stock.
CRBP strangle setup
The CRBP strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CRBP near $11.11, the first option leg uses a $11.67 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CRBP chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CRBP shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $11.67 | N/A |
| Buy 1 | Put | $10.55 | N/A |
CRBP strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
CRBP strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on CRBP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on CRBP
Strangles on CRBP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CRBP chain.
CRBP thesis for this strangle
The market-implied 1-standard-deviation range for CRBP extends from approximately $6.97 on the downside to $15.25 on the upside. A CRBP long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CRBP IV rank near 38.80% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on CRBP should anchor more to the directional view and the expected-move geometry. As a Healthcare name, CRBP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CRBP-specific events.
CRBP strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CRBP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CRBP alongside the broader basket even when CRBP-specific fundamentals are unchanged. Always rebuild the position from current CRBP chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on CRBP?
- A strangle on CRBP is the strangle strategy applied to CRBP (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CRBP stock trading near $11.11, the strikes shown on this page are snapped to the nearest listed CRBP chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CRBP strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CRBP strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 130.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CRBP strangle?
- The breakeven for the CRBP strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CRBP market-implied 1-standard-deviation expected move is approximately 37.30%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on CRBP?
- Strangles on CRBP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CRBP chain.
- How does current CRBP implied volatility affect this strangle?
- CRBP ATM IV is at 130.10% with IV rank near 38.80%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.